Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura.
COVID-19
TTP
caplacizumab
Journal
Hematology reports
ISSN: 2038-8322
Titre abrégé: Hematol Rep
Pays: Switzerland
ID NLM: 101556723
Informations de publication
Date de publication:
20 Jul 2023
20 Jul 2023
Historique:
received:
27
03
2023
revised:
28
04
2023
accepted:
12
07
2023
medline:
25
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening, rare acute thrombotic microangiopathy (TMA), caused by a severe ADAMTS13 deficiency. As the COVID-19 pandemic rapidly spread around the globe, much data about the pathogenicity of this virus were published. Soon after the detection of the first cases of COVID-19, it was clear that there was a wide range of COVID coagulopathy manifestations, such as deep venous thrombosis, pulmonary thromboembolism, and thrombotic microangiopathies. In the literature, little data have been reported about the association between TTP and COVID-19, and the treatment of COVID-19-associated TTP is still under debate. Here we present the case of a 46-year-old woman who developed a COVID-associated TTP, successfully treated with plasma exchange (PEX), steroids, and caplacizumab.
Identifiants
pubmed: 37489376
pii: hematolrep15030046
doi: 10.3390/hematolrep15030046
pmc: PMC10366750
doi:
Types de publication
Case Reports
Langues
eng
Pagination
448-453Références
Eur J Case Rep Intern Med. 2020 Dec 15;7(12):002143
pubmed: 33457377
Hematol Oncol Stem Cell Ther. 2011;4(2):51-9
pubmed: 21727765
Int Immunopharmacol. 2021 Apr;93:107397
pubmed: 33524803
Blood. 2012 Aug 9;120(6):1157-64
pubmed: 22611154
Cell. 1998 Sep 4;94(5):657-66
pubmed: 9741630
Blood. 1997 Dec 1;90(11):4413-24
pubmed: 9373252
BMJ Case Rep. 2020 Dec 17;13(12):
pubmed: 33334760
Int J Antimicrob Agents. 2020 Aug;56(2):105974
pubmed: 32298745
J Thromb Haemost. 2017 Feb;15(2):312-322
pubmed: 27868334
Hematol Rep. 2022 Aug 02;14(3):253-260
pubmed: 35997402
N Engl J Med. 2019 Jan 24;380(4):335-346
pubmed: 30625070
Blood. 1996 May 15;87(10):4235-44
pubmed: 8639782
Cureus. 2021 Jul 11;13(7):e16311
pubmed: 34405070
Thromb Haemost. 1997 Jul;78(1):434-8
pubmed: 9198192
Lancet Haematol. 2017 Apr;4(4):e157-e164
pubmed: 28259520
N Engl J Med. 2002 Aug 22;347(8):589-600
pubmed: 12192020
J Pak Med Assoc. 2023 Feb;73(2):407-409
pubmed: 36800739
Transfusion. 2020 Sep;60(9):2047-2057
pubmed: 32757237
N Engl J Med. 1998 Nov 26;339(22):1578-84
pubmed: 9828245
Crit Care Med. 2006 Aug;34(8):2127-33
pubmed: 16763519
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Clin Transl Sci. 2020 Nov;13(6):1087-1095
pubmed: 32881340
J Thromb Haemost. 2020 Oct;18(10):2486-2495
pubmed: 32914582
Intern Emerg Med. 2020 Nov;15(8):1375-1387
pubmed: 32653981
Sci Rep. 2016 Aug 26;6:32188
pubmed: 27561337
Blood. 1996 May 15;87(10):4223-34
pubmed: 8639781
J Thromb Thrombolysis. 2021 Aug;52(2):468-470
pubmed: 33389519
Transfusion. 2007 Sep;47(9):1710-6
pubmed: 17725738